Advaxis Inc. (NASDAQ:ADXS) shot up 4.8% during mid-day trading on Monday . The company traded as high as $14.51 and last traded at $14.36, with a volume of 801,585 shares changing hands. The stock had previously closed at $13.70.

A number of brokerages have recently issued reports on ADXS. Jefferies Group restated a “buy” rating on shares of Advaxis in a research note on Thursday, August 4th. HC Wainwright restated a “buy” rating and issued a $23.00 target price on shares of Advaxis in a research note on Friday, August 5th. Barclays PLC upped their target price on shares of Advaxis from $15.00 to $20.00 and gave the company an “overweight” rating in a research note on Wednesday, August 3rd. Finally, FBR & Co restated an “outperform” rating and issued a $34.00 target price on shares of Advaxis in a research note on Thursday, July 7th. Six analysts have rated the stock with a buy rating, Advaxis currently has a consensus rating of “Buy” and a consensus price target of $25.80.

The firm’s 50 day moving average price is $10.51 and its 200 day moving average price is $8.66. The firm’s market capitalization is $492.18 million.

In other news, Director David Sidransky sold 22,808 shares of the stock in a transaction on Tuesday, August 9th. The shares were sold at an average price of $15.01, for a total transaction of $342,348.08. Following the transaction, the director now owns 91,759 shares in the company, valued at approximately $1,377,302.59. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Richard J. Berman sold 18,000 shares of the stock in a transaction on Monday, August 8th. The stock was sold at an average price of $15.21, for a total transaction of $273,780.00. Following the transaction, the director now owns 66,430 shares in the company, valued at approximately $1,010,400.30. The disclosure for this sale can be found here.

Advaxis, Inc is a clinical-stage biotechnology company. The Company’s immunotherapies are based on a platform technology that utilizes live attenuated Listeria monocytogenes (Lm or Listeria) bioengineered to secrete antigen/adjuvant fusion proteins. It is focused on the discovery, development and commercialization of Lm-LLO cancer immunotherapies.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.